Announcing Grants for Emerging Medical Device Companies
Arizona has one of the fastest growing bioscience communities in the US; annual total economic activity is now $28.8 billion. It has a particularly robust medical device sector, which constitutes 32% of Arizona’s non-hospital bioscience employment. With first-class research institutions and an industry spanning from one-person shops to industry giants, Arizona has it all.To support this critically important sector, the City of Peoria, Arizona, BioAccel and The Plaza Companies have created BioInspire™, an incubator in Peoria dedicated to medical device development that provides working capital and space to qualifying companies. More than just a facility, this collaboration was created to connect the medical device community.
Arizona Commerce Authority05/17/2013
AZ Innovation Challenge Video
The Arizona Innovation Challenge (AIC), powered by the Arizona Commerce Authority , awards the most money in the country for a technology commercialization challenge – $3 million ($1.5 million twice yearly) to the world’s most promising technology ventures. Awards range from $100,000 to $250,000 per company. The results? A big-time investment in the most talented entrepreneurs. Bringing to market products that are literally changing the way the world works. Driving wealth and job creation for the state of Arizona. Are you up for the Challenge?
Partnering in the New Age of R&D
There is a major shift occurring in our industries with companies large and small. None of us are looking to go it alone in a world where new product development can range from millions to BILLIONS. Again we looked to experts from the front lines for insights... Panelists: Paul August, VP and head of the early to candidate program for Sanofi, US ; Babak Nemat of founder of Strategic Intelligence and advisor to J&J, Bill Mulholland of Snell & Wilmer, Joan Koerber-Walker, AZBio (moderator)
Harry A. George, 2012 Bioscience Leader of the Year
For close to four decades, Harry George has been creating, capitalizing, and operating rapid-growth technology companies. A quiet, action oriented leader. Harry has consistently driven Arizona’s bioscience and technology sectors forward by acting on his vision with commitment, dedication, and determination. In recognition of his service and accomplishments, Harry A. George is the 2012 Jon W. McGarity Bioscience Leader of the Year
Innovation Local Business Incubator Transforms Science Into Marketable Applications
Transforming Innovation into Business Northern Arizona Center for Entrepreneurship and Technology fosters business growth and economic vitality, creating high-quality jobs for the region. Partnering with a wide variety of non-retail, service, manufacturing, high technology, science and renewable energy firms, NACET offers a hands-on business incubation engagement program designed to transform innovation into viable companies. NACET’s powerful program matches great ideas with the appropriate resources. We not only link our client companies to specialty labs and equipment, intellectual property and capital resources, but we also create synergies through an extensive network of mentors, faculty, staff, interns and alumni from local businesses and academic institutions. Located on the burgeoning business campus near Buffalo Park in Flagstaff, Ariz., NACET offers a beautiful, state-of-the-art facility with affordable office and meeting space, administrative support services, fully-equipped laboratory space and advanced communications technology. NACET – Your Business Resource NACET’s extensive business acumen and resources could be the catalyst you need to transform your innovation into a viable company. Find out how we can help.
2012 AZBio Fast Lane Award Winner - Ulthera
Beauty and Growth – Ulthera, Inc Ulthera’s mission is to work with physicians to provide therapeutic ultrasound to improve the appearance and health of patients worldwide. The company is not only defined by its proprietary technology, but also its people. Ulthera’s team consists of experts in their respective fields who are aligned by the strength of the company’s mission and its leadership. Ulthera was founded in 2004 to leverage seven years of prior scientific research in therapeutic ultrasound for aesthetic and medical applications. In 2009, the Ulthera® System received FDA approval in the United States and is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. The first application for Ultherapy® – the procedure enabled by the System – is a non-invasive treatment of the face to achieve a brow lift. Ulthera’s robust scientific foundation and relentless pursuit of superior clinical outcomes have resulted in the rapid global uptake of the Ulthera platform. As Ulthera continues to develop and provide more applications for its platform, the company also remains committed to bringing value to physicians and their patients. In 2006, Matt Likens was hired as President and CEO of Ulthera by founder and owner Michael Slayton, Ph. D, with the expectation of obtaining FDA approval for Ulthera’s product and service (known as Ultherapy) within three months. Less than two years into his tenure at Ulthera, Matt found himself navigating this venture capital backed start-up though the worst economic downtown since the Great Depression. The Company also found itself facing an increasing skeptical and less commercially friendly US Food and Drug Administration (FDA) regime. With both of these risks significantly threatening the Company’s viability, Matt decided to change the Company’s regulatory pathway and focus by obtaining CE Mark from the European Union prior to obtaining FDA clearance. If this bet paid off, Ulthera’s regulatory runway would be significantly reduced and the Company would be able to generate sales in the European market. These revenues would also allow the Company to lessen the need to obtain additional venture capital financing thus reducing additional dilution to the Company’s current shareholders. While risky, the core of this decision was based on the multinational experience Likens attained at Baxter and his general entrepreneurial nature. The bet ultimately paid off. Today, Ulthera is a global, growth-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. More than 1,000 Ulthera Systems have been sold globally while treatments performed using the System have surpassed 100,000.